Dynavax Technologies Corp (DVAX)
11.25
-0.17
(-1.49%)
USD |
NASDAQ |
Apr 25, 13:21
Dynavax Technologies SG&A Expense (Quarterly): 41.28M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 41.28M |
September 30, 2023 | 38.05M |
June 30, 2023 | 37.07M |
March 31, 2023 | 36.54M |
December 31, 2022 | 31.02M |
September 30, 2022 | 32.04M |
June 30, 2022 | 36.18M |
March 31, 2022 | 32.17M |
December 31, 2021 | 29.22M |
September 30, 2021 | 26.93M |
June 30, 2021 | 21.58M |
March 31, 2021 | 22.42M |
December 31, 2020 | 17.84M |
September 30, 2020 | 21.54M |
June 30, 2020 | 18.95M |
March 31, 2020 | 20.93M |
December 31, 2019 | 20.32M |
September 30, 2019 | 18.46M |
June 30, 2019 | 17.86M |
March 31, 2019 | 18.35M |
December 31, 2018 | 16.44M |
September 30, 2018 | 15.79M |
June 30, 2018 | 15.65M |
March 31, 2018 | 16.89M |
December 31, 2017 | 9.256M |
Date | Value |
---|---|
September 30, 2017 | 6.027M |
June 30, 2017 | 5.612M |
March 31, 2017 | 6.472M |
December 31, 2016 | 8.171M |
September 30, 2016 | 11.77M |
June 30, 2016 | 9.151M |
March 31, 2016 | 8.169M |
December 31, 2015 | 6.699M |
September 30, 2015 | 5.524M |
June 30, 2015 | 5.098M |
March 31, 2015 | 4.859M |
December 31, 2014 | 5.052M |
September 30, 2014 | 4.214M |
June 30, 2014 | 4.263M |
March 31, 2014 | 4.234M |
December 31, 2013 | 3.708M |
September 30, 2013 | 6.725M |
June 30, 2013 | 7.636M |
March 31, 2013 | 8.80M |
December 31, 2012 | 9.293M |
September 30, 2012 | 7.121M |
June 30, 2012 | 5.957M |
March 31, 2012 | 5.793M |
December 31, 2011 | 4.545M |
September 30, 2011 | 4.217M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
17.84M
Minimum
Dec 2020
41.28M
Maximum
Dec 2023
27.39M
Average
26.93M
Median
Sep 2021
SG&A Expense (Quarterly) Benchmarks
Supernus Pharmaceuticals Inc | 81.28M |
Ligand Pharmaceuticals Inc | 15.99M |
Pacira BioSciences Inc | 65.80M |
Esperion Therapeutics Inc | 45.42M |
PetIQ Inc | 42.73M |